Affini-T Therapeutics’ KRAS TCR T Cell Therapy Program to be Presented at the Annual Meeting of the American Society of Gene and Cell Therapy

BOSTON, Mass., and SEATTLE, Wash. – May 3, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its KRAS program will be presented in an oral presentation at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The data […]

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

Co-founded at Fred Hutchinson Cancer Research Center with Phil Greenberg, M.D., Aude Chapuis, M.D., and Tom Schmitt, Ph.D., and Vida Ventures along with serial entrepreneurs Arjun Goyal, M.D., M.Phil., and Jak Knowles, M.D. Foundational cell therapy platform builds upon seminal work from co-founders, leveraging a T Cell Receptor (TCR) discovery engine and suite of synthetic […]

Affini-T Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON, Mass., and SEATTLE, Wash., Jan. 10, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. Jak Knowles, M.D., Co-Founder, President and Chief Executive Officer, will present an overview of the company at 2:00 […]